|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.40/--
|
企業價值
17.41M
|
資產負債 |
每股賬面淨值
-0.26
|
現金流量 |
現金流量率
--
|
損益表 |
收益
1.93M
|
每股收益
0.38
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/01/11 11:21 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs). |